Aegerion Pharmaceuticals Downgraded to “Market Perform” at Cowen and Company (AEGR)
Aegerion Pharmaceuticals (NASDAQ:AEGR) was downgraded by stock analysts at Cowen and Company from an “outperform” rating to a “market perform” rating in a report issued on Wednesday, TheFlyOnTheWall.com reports.
In other Aegerion Pharmaceuticals news, Insider Craig Fraser sold 2,250 shares of the company’s stock on the open market in a transaction dated Wednesday, April 30th. The shares were sold at an average price of $43.55, for a total value of $97,987.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
Aegerion Pharmaceuticals (NASDAQ:AEGR) opened at 44.16 on Wednesday. Aegerion Pharmaceuticals has a one year low of $40.16 and a one year high of $101.00. The stock has a 50-day moving average of $44.82 and a 200-day moving average of $61.45. The company’s market cap is $1.299 billion.
Aegerion Pharmaceuticals (NASDAQ:AEGR) last released its earnings data on Tuesday, May 6th. The company reported ($0.25) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.35) by $0.10. The company had revenue of $27.00 million for the quarter, compared to the consensus estimate of $33.58 million. Analysts expect that Aegerion Pharmaceuticals will post $-0.36 EPS for the current fiscal year.
AEGR has been the subject of a number of other recent research reports. Analysts at FBR Capital Markets cut their price target on shares of Aegerion Pharmaceuticals from $111.00 to $107.00 in a research note on Wednesday. They now have an “outperform” rating on the stock. Separately, analysts at Jefferies Group cut their price target on shares of Aegerion Pharmaceuticals from $80.00 to $61.00 in a research note on Wednesday. Finally, analysts at Ned Davis Research upgraded shares of Aegerion Pharmaceuticals from a “sell” rating to a “neutral” rating in a research note on Monday, April 21st. Three research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $90.14.
Aegerion Pharmaceuticals, Inc (NASDAQ:AEGR) is a biopharmaceutical company focused on the development and commercialization of therapeutics to treat lipid disorders.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.